Insomnia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Insomnia Pipeline Drugs Market Report Overview
Insomnia is a sleep disorder that is characterized by difficulty falling and/or staying asleep. Symptoms include difficulty falling asleep at night, irritability, depression or anxiety, tension headaches, and distress in the stomach and intestines. Risk factors include age, mental health disorders, stress, and shift working.
The Insomnia pipeline drugs market research report provides comprehensive information on the therapeutics under development for Insomnia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report offers an overview of key players involved in therapeutic development for Insomnia and features dormant and discontinued projects.
Insomnia Pipeline Drugs Market Segmentation by Targets
Some of the targets of the Insomnia pipeline drugs market are Orexin Receptor Type 2, Cannabinoid Receptor 1, Cannabinoid Receptor 2, Orexin Receptor Type 1, Melatonin Receptor Type 1A, Melatonin Receptor Type 1B, Gamma-Aminobutyric Acid Receptor Subunit Alpha 1, and Gamma-Aminobutyric Acid Type A Receptor Subunit.
Insomnia Pipeline Drugs Market Analysis, by Targets
For more Insomnia pipeline drugs market target insights, download a free report sample
Insomnia Pipeline Drugs Market Segmentation by Mechanism of Actions
Some of the mechanisms of action of the Insomnia pipeline drugs market are Orexin Receptor Type 2 Antagonist, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, Orexin Receptor Type 1 Antagonist, Melatonin Receptor Type 1A Agonist, Melatonin Receptor Type 1B Agonist, Gamma-Aminobutyric Acid Receptor Subunit Alpha 1 Agonist, and Gamma-Aminobutyric Acid Type A Receptor Subunit Agonist.
Insomnia Pipeline Drugs Market Analysis, by Mechanism of Actions
For more mechanism of action insights into the Insomnia pipeline drugs market, download a free report sample
Insomnia Pipeline Drugs Market Segmentation by Routes of Administration
The key routes of administration in the Insomnia pipeline drugs market are oral, sublingual, intravenous, nasal, transdermal, buccal, inhalational, and parenteral.
Insomnia Pipeline Drugs Market Analysis, by Routes of Administration
For more routes of administration insights into the Insomnia pipeline drugs market, download a free report sample
Insomnia Pipeline Drugs Market Segmentation by Molecule Types
The molecule types in the Insomnia pipeline drugs market are Small Molecule and Biologic.
Insomnia Pipeline Drugs Market Analysis, by Molecule Types
For more molecule type insights into the Insomnia pipeline drugs market, download a free report sample
Competitive Landscape
Some of the key companies in the Insomnia pipeline drugs market are Idorsia Pharmaceutical Ltd, Taisho Pharmaceutical Holdings Co Ltd, Zelira Therapeutics Ltd, Evotec SE, Imbrium Therapeutics LP, Johnson & Johnson, and Acahealth Pharma and Biotech Co Ltd.
Insomnia Pipeline Drugs Market Analysis, by Companies
To know more about the Insomnia pipeline drugs market companies, download a free report sample
Insomnia Pipeline Drugs Market Report Overview
Key Targets | Orexin Receptor Type 2, Cannabinoid Receptor 1, Cannabinoid Receptor 2, Orexin Receptor Type 1, Melatonin Receptor Type 1A, Melatonin Receptor Type 1B, Gamma-Aminobutyric Acid Receptor Subunit Alpha 1, and Gamma-Aminobutyric Acid Type A Receptor Subunit |
Key Mechanism of Actions | Orexin Receptor Type 2 Antagonist, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, Orexin Receptor Type 1 Antagonist, Melatonin Receptor Type 1A Agonist, Melatonin Receptor Type 1B Agonist, Gamma-Aminobutyric Acid Receptor Subunit Alpha 1 Agonist, and Gamma-Aminobutyric Acid Type A Receptor Subunit Agonist |
Key Routes of Administration | Oral, Sublingual, Intravenous, Nasal, Transdermal, Buccal, Inhalational, and Parenteral |
Key Molecule Types | Small Molecule and Biologic |
Key Companies | Idorsia Pharmaceutical Ltd, Taisho Pharmaceutical Holdings Co Ltd, Zelira Therapeutics Ltd, Evotec SE, Imbrium Therapeutics LP, Johnson & Johnson, and Acahealth Pharma and Biotech Co Ltd |
Scope
This report provides:
- A snapshot of the global therapeutic landscape of Insomnia.
- Reviews of pipeline therapeutics for Insomnia by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- Descriptive drug profiles for the pipeline products which comprise product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- Reviews key companies involved in Insomnia therapeutics and enlists all their major and minor projects.
- Evaluation of Insomnia therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- All the dormant and discontinued pipeline projects.
- Reviews of the latest news related to pipeline therapeutics for Insomnia.
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with a potentially strong product portfolio and create effective counterstrategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Insomnia.
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Insomnia pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Bod Australia Ltd
Cannabis Science Inc
Cennerv Pharma (S) Pte Ltd
Closed Loop Medicine Ltd
Eisai Co Ltd
EUSOL Biotech Co Ltd
Evotec SE
Idorsia Pharmaceutical Ltd
Imbrium Therapeutics LP
Intra-Cellular Therapies Inc
Johnson & Johnson
LP Pharmaceutical (Xiamen) Co Ltd
M et P Pharma AG
NB Health Laboratory Co Ltd
Neurim Pharmaceuticals Ltd
Neurofix Pharma SA
NovaMedica
Servatus Ltd
Shackelford Pharma Inc
Sinsin Pharmaceutical Co Ltd
Taisho Pharmaceutical Holdings Co Ltd
Yangtze River Pharmaceutical Group
Zelira Therapeutics Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets of the Insomnia pipeline drugs market?
Some of the key targets of the Insomnia pipeline drugs market are the Orexin Receptor Type 2, Cannabinoid Receptor 1, Cannabinoid Receptor 2, Orexin Receptor Type 1, Melatonin Receptor Type 1A, Melatonin Receptor Type 1B, Gamma-Aminobutyric Acid Receptor Subunit Alpha 1, and Gamma-Aminobutyric Acid Type A Receptor Subunit.
-
What are the key mechanisms of action in the Insomnia pipeline drugs market?
Some of the key mechanisms of action in the Insomnia pipeline drugs market are Orexin Receptor Type 2 Antagonist, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, Orexin Receptor Type 1 Antagonist, Melatonin Receptor Type 1A Agonist, Melatonin Receptor Type 1B Agonist, Gamma-Aminobutyric Acid Receptor Subunit Alpha 1 Agonist, and Gamma-Aminobutyric Acid Type A Receptor Subunit Agonist.
-
What are the key routes of administration in the Insomnia pipeline drugs market?
The key routes of administration in the Insomnia pipeline drugs market are oral, sublingual, intravenous, nasal, transdermal, buccal, inhalational, and parenteral.
-
What are the key molecule types in the Insomnia pipeline drugs market?
The molecule types in the Insomnia pipeline drugs market are Small Molecule and Biologic.
-
Which are the key companies in the Insomnia pipeline drugs market?
Some of the key companies in the Insomnia pipeline drugs market are Idorsia Pharmaceutical Ltd, Taisho Pharmaceutical Holdings Co Ltd, Zelira Therapeutics Ltd, Evotec SE, Imbrium Therapeutics LP, Johnson & Johnson, and Acahealth Pharma and Biotech Co Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.